New developments in 2021

Customer needs drive the development of Reaxys and Reaxys Medicinal Chemistry, ensuring a best-in-class solution for successful chemical sciences and pharmaceutical research and development.

Stay on top of your field

In early 2021, users can easily search for bibliographic information and claims for newly published patents from 105 patent offices and 170 IPC classes. Content will be indexed and added to Reaxys just 5 days after publication, meaning users can stay on top of new developments.

Accelerate competitive intelligence

In Q2 and Q3, users will have fast and comprehensive access to protein target data extracted from patents from 12 essential offices. This valuable information will be available and searchable just 5 days after publication. This means users can more quickly validate targets, understanding what is known about them and who is working on them.

Perform novelty searches

In the second half of 2021 and early 2022, users will also be able to access substance data extracted from patents from 12 essential offices. Again, this valuable information will be available and searchable just 5 days post-publication. Making this content easily searchable enables novelty searching for identified hits, which is crucial to assessing intellectual property exclusivity.

New possibilities for competitive intelligence and novelty searches

- Access to claims from over 100 patent offices and all IPC classes
- Access to target and substance data from 12 patent offices
- Fast turnaround with just 5 days from publication to inclusion in Reaxys
- Indispensable information for chemical and drug R&D
Improved experiences in synthesis planning and more

- Incorporate standard synthesis planning and predicted retrosynthesis in one workflow
- Easily compare predicted and published reactions for synthesis plans
- Quickly navigate Reaxys examples and reaction conditions
- Enjoy more flexible searching between Scopus® and Reaxys®

Enjoy improved synthesis planning
In the first half of 2021, the improved user interface for Synthesis Planner will launch, enabling researchers to:

- Quickly review current and past searches for quicker comparison of results
- More easily navigate examples and conditions drawn from Reaxys’ vast database
- Export selected results in formats suitable for every workflow

In addition, users with access to the powerful Reaxys Predictive Retrosynthesis module will be able to incorporate standard synthesis planning and predictive retrosynthesis in one workflow. They can also view predicted and published reactions together, including citations and conditions. This integrated interface approach will save time and improve productivity.

Reaxys Predictive Retrosynthesis enables the generation of robust synthesis route suggestions for small organic molecules. Developed in partnership with Dr. Mark Waller, it is a best-in-class AI-based solution that:

- Leverages comprehensive reaction data and deep neural network technology
- Directly and intuitively links predictions and experimental evidence
- Provides customization options to include your own reactions

Get even easier access to commercial supplier information
In Q1 2021, users can indicate preferred suppliers and create shopping lists for available products thanks to improved Reaxys Commercial Suppliers functionality. These new features ensure that researchers and purchasers can efficiently investigate the products they need for their workflows.

The new preferred supplier functionality means that users will immediately find information about the suppliers your company wants to work with. The ability to create a shopping list of interesting products increases the efficiency of purchasing workflows.

Enjoy more flexible searching with Scopus and Reaxys
In Q2 2021, users with access to both Scopus and Reaxys will have an enriched search experience. Substance and experimental data for a given article will be available for its abstract in Scopus, enriching the reading experience and making it easier to assess a document’s relevance and quality. Links to commercial availability and synthesis planning are also planned. This will streamline the planning phase of projects and experiments.

For more information, contact your Elsevier sales representative.